Pharvaris (NASDAQ:PHVS) Trading Down 7.9% – Time to Sell?

Pharvaris (NASDAQ:PHVS) shares traded down 7.9% during trading on Thursday . The company traded as low as $22.99 and last traded at $23.03. 29,500 shares were traded during trading, a decline of 67% from the average session volume of 89,179 shares. The stock had previously closed at $25.01.

Analyst Upgrades and Downgrades

Separately, Oppenheimer boosted their price target on shares of Pharvaris from $38.00 to $42.00 and gave the company an “outperform” rating in a research report on Friday, September 6th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $33.60.

Pharvaris Stock Up 1.3 %

The stock’s fifty day simple moving average is $20.54 and its two-hundred day simple moving average is $19.44.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.02). As a group, equities analysts expect that Pharvaris will post -2.69 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PHVS. Sofinnova Investments Inc. raised its position in Pharvaris by 2.9% in the second quarter. Sofinnova Investments Inc. now owns 601,534 shares of the company’s stock worth $11,309,000 after acquiring an additional 16,862 shares during the period. Deerfield Management Company L.P. Series C raised its position in Pharvaris by 31.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company’s stock worth $26,269,000 after acquiring an additional 335,687 shares during the period. Finally, Novo Holdings A S raised its position in Pharvaris by 47.7% in the second quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock worth $32,430,000 after acquiring an additional 556,970 shares during the period.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.